Gilead Sciences Inc. is moving further into inflammatory diseases in a potential $1.7 billion deal with Leo Pharma A/S around a preclinical oral signal transduction and activator of transcription 6 ...

So far, the FDA has approved the drug only for people who already have HIV that’s resistant to other treatments. But its ...

With incoming president Donald Trump threatening a trade war with China, experts told BioSpace that the new administration ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Just a week before he vacates the White House, President Biden signed the Interim Final Rule on Artificial Intelligence ...

Two moon landers, one from Japan's ispace and another from U.S. space firm Firefly, began their journeys into space on Wednesday (January 15) with SpaceX's unusual double moonshot launch, underscoring ...

President Joe Biden will cap his half-century political career with a final Oval Office speech, hoping to cement a legacy ...

The US and China are engaged in an arms race in this area. Chinese company Huawei is a leading player in the development of Chinese graphics processors that form the basis of the country’s ...

Biden decided not to include Israel among the countries exempt from the approval process, namely Australia, Belgium, Canada, Denmark, Finland, Germany, France, French Guiana, Ireland, Italy, Japan, ...

Credit: Kmpzzz/Shutterstock. Gilead Sciences and LEO Pharma have entered a strategic collaboration to expedite the development and commercialisation of the latter’s small molecule oral signal ...

Will 2025 be China’s year? Chinese stocks sprang higher in the fourth quarter, as Beijing unleashed measures to stimulate demand and lift prices, including rate cuts, homebuying incentives ...